Gw. Boland et al., INDETERMINATE ADRENAL MASS IN PATIENTS WITH CANCER - EVALUATION AT PET WITH 2-[F-18]-FLUORO-2-DEOXY-D-GLUCOSE, Radiology, 194(1), 1995, pp. 131-134
PURPOSE: To evaluate the ability of positron emission tomography (PET)
to characterize adrenal masses in patients with cancer. MATERIALS AND
METHODS: Twenty-four adrenal masses (size range, 1.5-10.0 cm [mean, 2
.8 cm]) in 20 patients (13 men and seven women) with cancer (lung [n =
10], colon [n = 3], lymphoma [n = 3], miscellaneous [n = 4]) were eva
luated. PET was performed in fasting patients 45 minutes after infusio
n of 5-10 mCi (185-370 MBq) of 2-[fluorine-18]-fluoro-2-deoxy-D-glucos
e (FDG). PET images were correlated with findings at computed tomograp
hy (CT), surgery, and/or percutaneous biopsy. RESULTS: Fourteen adrena
l masses were proved malignant at surgery fn = 4), biopsy (n = 7), or
follow-up (n = 3). Ten lesions were proved benign at biopsy (n = 4) or
follow-up CT (n = 6). PET helped correct differentiation of benign fr
om malignant adrenal lesions in all patients. A statistically signific
ant difference (P < .001) was seen between mean tumor-to-background ra
tios for malignant (mean, 7.4; range, 2.9-16.6; median, 6.9) versus be
nign (mean, 0.8; range, 0.2-1.2; median, 0.6) adrenal lesions. CONCLUS
ION: PET helped correct differentiation of benign from malignant adren
al lesions.